Bristol Myers (NYSE: BMY) EVP reports award vesting, tax withholding and new grants
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Bristol Myers Squibb executive Adam Lenkowsky reported multiple stock-based compensation events involving common stock and performance-linked awards. On March 10, 2026, he exercised or settled derivative awards covering 24,071 shares tied to market share units and performance shares, with no open‑market purchases or sales.
The filing shows 7,015 common shares withheld at $60.13 per share to satisfy tax obligations as awards vested. Lenkowsky also received new long-term incentives, including 32,653 market share units and 48,980 performance share units scheduled to run to 2029, all linked to Bristol Myers Squibb common stock.
After these transactions, he directly holds 19,135 shares of common stock, plus indirect holdings of 5,849.47 shares through a BMS savings and investment program and 2,929 shares held by his spouse. Footnotes clarify these events reflect routine vesting, performance adjustments, and tax withholding under the company’s long-term incentive plans.
Positive
- None.
Negative
- None.
Insider Trade Summary
24,071 shares exercised/converted
Mixed
20 txns
Insider
Lenkowsky Adam
Role
EVP, Chief Commercial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Market Share Units | 1,828 | $0.00 | -- |
| Exercise | Market Share Units | 2,000 | $0.00 | -- |
| Exercise | Performance Shares | 12,002 | $0.00 | -- |
| Exercise | Performance Shares | 8,241 | $0.00 | -- |
| Grant/Award | Market Share Units | 32,653 | $0.00 | -- |
| Grant/Award | Performance Shares | 48,980 | $0.00 | -- |
| Exercise | Common Stock, $0.10 par value | 1,828 | $0.00 | -- |
| Other | Common Stock, $0.10 par value | 205 | $0.00 | -- |
| Tax Withholding | Common Stock, $0.10 par value | 831 | $60.13 | $50K |
| Exercise | Common Stock, $0.10 par value | 2,000 | $0.00 | -- |
| Other | Common Stock, $0.10 par value | 216 | $0.00 | -- |
| Tax Withholding | Common Stock, $0.10 par value | 913 | $60.13 | $55K |
| Exercise | Common Stock, $0.10 par value | 12,002 | $0.00 | -- |
| Other | Common Stock, $0.10 par value | 5,893 | $0.00 | -- |
| Tax Withholding | Common Stock, $0.10 par value | 3,125 | $60.13 | $188K |
| Exercise | Common Stock, $0.10 par value | 8,241 | $0.00 | -- |
| Other | Common Stock, $0.10 par value | 4,046 | $0.00 | -- |
| Tax Withholding | Common Stock, $0.10 par value | 2,146 | $60.13 | $129K |
| holding | Common Stock, $0.10 par value | -- | -- | -- |
| holding | Common Stock, $0.10 par value | -- | -- | -- |
Holdings After Transaction:
Market Share Units — 0 shares (Direct);
Performance Shares — 0 shares (Direct);
Common Stock, $0.10 par value — 14,267 shares (Direct);
Common Stock, $0.10 par value — 5,849.47 shares (Indirect, BMS Savings and Investment Program)
Footnotes (1)
- Represents vesting of one-quarter of market share units granted on March 10, 2022. Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Shares withheld for payment of taxes upon vesting of awards. Represents vesting of one-quarter of market share units granted on March 10, 2023. Amount represents distribution of performance shares earned under the 2023-2025 Long-Term Performance Award. Adjustment to award based on the performance factor applied in accordance with the terms of the award and certification of performance results by the Board. Based on recent 401(k) plan statement. Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2026. Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is the greater of Total Return and relative total shareholder return (rTSR) Floor. Total Return is a ratio of the 10-day average closing stock price on the measurement date, plus the value of accumulated dividends, divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor for Total Return performance that must be achieved to earn a payout is 80% and the maximum is 225%. The rTSR Floor feature provides a minimum level of payout if BMS stock price declines from the grant date but outperforms our peers based on their TSR percentile rank. A TSR percentile rank (i) below the 50th percentile yields a 0% payout, (ii) between the 50th and 74.99th percentiles yields a 50% payout, and (iii) at or above the 75th percentile yields a 100% payout. These market share units cliff vest on the third anniversary of the grant date, subject to certification of performance results by the Board. Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2029, subject to certification of performance results by the Board.
FAQ
What did Bristol Myers (BMY) EVP Adam Lenkowsky report in this Form 4?
Adam Lenkowsky reported routine stock-based compensation activity, including vesting and exercise of performance-linked awards and related tax withholding. The events converted derivative awards into Bristol Myers Squibb common stock without any open-market purchases or sales disclosed in the filing.
What new long-term incentive awards did Adam Lenkowsky receive from Bristol Myers (BMY)?
He received 32,653 market share units and 48,980 performance share units linked to Bristol Myers Squibb common stock. Footnotes state these awards vest or distribute around 2029, subject to performance certification by the Board and specific payout formulas.
Were Adam Lenkowsky’s Bristol Myers (BMY) transactions open-market buys or sells?
No open-market purchases or sales are shown. The Form 4 reflects derivative exercises, distributions of performance-based awards, tax withholding transactions, and routine adjustments tied to long-term incentive plans, rather than discretionary market trading.